Abstract
A case of a 65-year-old woman with a pancreatic tumor secreting insulin, glucagon, and associated with high PTH levels and hypercalcemia is reported. The patient underwent two Streptozotocin (STZ) treatments (1 g iv/week for 10 weeks) after liver metastases were found. Hormonal and metabolic parameters were monitorized. Before the first STZ treatment insulin levels ranged between 78 and 132 μU/ml. After STZ administration insulin decreased and then remained lower (8–48 μU/ml) until the death of the patient. Pre-treatment glucagon levels ranged between 1.3 and 3.9 ng/ml. STZ induced a decrease of glucagon to 0.5 ng/ml. Glucagon chromatography revealed the prevalence of high molecular weight (> 6,000 mol wt) immunoreactive glucagon (0.9 ng/ml) drastically reduced by STZ treatment (0.15 ng/ml). Hypoaminoacidemia was observed before STZ administration, but at the end of the therapy plasma amino acid concentrations were normal. Hypercalcemia too was sensitive to STZ, but not PTH value, which remained high. The second STZ treatment performed a year later was less effective and so a chemotherapeutic protocol was started. Our findings suggest a cytolitic effect of STZ on malignant A-cell, with reduction of glucagon levels and restoration of amino acid metabolism. This effect would be useful for medical treatment of non-operable glucagon secreting tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Higgins G.A., Racant L., Fischman A.B. The glucagonoma syndrome: surgically curable diabetes. Am. J. Surg. 137: 142, 1979.
Strauss G.M., Weitzman S.A., Aoki T.T. Dimethyltriazenoimidazole carboxamide therapy of malignant glucagonoma. Ann. Intern. Med. 90: 57, 1979.
Kessinger A., Lemon H.M., Foley J.P. The glucagonoma syndrome and its management. J. Surg. Oncol. 9: 419, 1977.
Marynick S.P., Warren R.F., Ducan L.A. Malignant glucagonoma syndrome: response to chemotherapy. Ann. Intern. Med. 93: 453, 1980.
Moertel C.G., Hanley J.A., Johnson L.A. Streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 303: 1189, 1980.
Broder L.E., Carter S.K. Pancreatic, islet carcinoma. I. Clinical features of 52 patients. J. Am. Intern. Med. 79: 101, 1973.
Broder L.E., Carter S.K. Pancreatic islet carcinoma. II. Results of therapy with streptozotocin in 52 patients. J. Am. Intern. Med. 79: 108, 1973.
Lokich J., Anderson N., Rossini A., Hadley W., Federman M., Legg M. Pancreatic alpha cell tumours: case report and review of the literature. Cancer 45: 2675, 1980.
Murray-Iyon I.M., Eddleston A.L.W.F., Williams R., Brown M., Hogibin B.M., Bennetta E.J.C., Taylor K.W. Treatments of multiple-hormone-producing malignant islet-cell tumours with streptozotocin. Lancet 2: 895, 1968.
Danfort D.N., Triche T., Doppman J.L., Beazley R.M., Perrino P.V., Recant L. Elevated plasma proglucagon-like components with a glucagon-secreting tumor. Effect of streptozotocin. N. Engl. J. Med. 295: 242, 1976.
Tiengo A., Fedele D., Marchiori E., Nosadini R., Muggeo M. Suppression and stimulating mechanism controlling glucagon secretion in a case of islet-cell tumor producing glucagon, insulin and gastrin. Diabetes 25: 408, 1976.
Arnoud CD., Tsao H.S., Littldike T. Radioimmunoassay of human parathyroid hormone in serum. J. Clin. Invest. 50: 21, 1971.
Valverde I., Villanueva M.L., Lonzano I., Marco J. Presence of glucagon immunoreactivity in the globulin fraction of human plasma (“Big plasma glucagon”). J. Clin. Endocrinol. Metab. 39: 1090, 1974.
Valverde I., Dobbs R., Unger R.H. Heterogeneity of plasma -glucagon immunoreactivity in normal, depancreatized and alloxan diabetic dogs. Metabolism, 24: 1021, 1975.
Marescotti M.C., Trevisan R., Avogaro A. Determinazione degli aminoacidi plasmatici mediante cromatografia in fase liquida. Lab. (In press).
Valverde I. Quantification of plasma glucagon immunoreactive components in normal and hyperglucagonemic status. In: Foà P.P., Bajaj Y.S., Foà M.L. (Eds.), Glucagon its role in physiology and clinical medicine. Springer Verlag, New York, 1977, p. 77.
Creutzfeld A.R., Creutzfeld W. Multiple hormone production of endocrine tumours of gastrointestinal tract. James V.H.J. In: (Ed.), Endocrinology, Excerpta Medica, Amsterdam, 1977, vol. 2, p. 132.
Larsson L.I., Grimelius L., Hakanson R., Rehfeld J.F., Stadil F., Hoist J., Angervall L., Sundler F. Mixed endocrine tumours producing several peptide hormones. Am. J. Pathol. 79: 271, 1975.
Hammar S. Sale G. Multiple hormone producing islet cell carcinomas of the pancreas. Hum. Pathol. 6: 349, 1975.
Ohneda A., Otsuki M., Fujiya H., Yaginuma N., Kokubo T., Ohtani H. A malignant insulinoma transformed into a glucagonoma syndrome. Diabetes 28: 962, 1979.
Berger M., Teuscher A., Halban P., Trimble E., Studer P.P., Wollheim C.B., Zimmerman-Telschow H., Muller A. In vitro and in vivo studies on glucagonoma tissue. Horm. Metab. Res. 12: 144, 1980.
Croughs R.J.M., Hulsmans H.A., Israel D.E., Hackeg W.H., Schopman W. Glucagonoma as part of polyglandular adenoma syndrome. Am. J. Med. 52: 690, 1972.
Recant L., Perrino P.V., Bathena S.J., Danforth D.N., Lavine R.L. Plasma immunoreactive glucagon fractions in four cases of glucagonoma: increased “Large glucagon immunoreactivity”. Diabetologia 12: 319, 1976.
Valverde I., Lemon H.M., Kissinger A., Unger R.H. Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma. J. Clin. Endocrinol. Metab. 42: 804, 1976.
Gutman R.A., Lazarus N.R., Penhos J.C., Fajans S., Recant L. Circulating proinsulin-like material in patients with functioning insulinomas. N. Engl. J. Med. 284: 1003, 1971.
Yalow R.S., Berson S.A. Big big insulin. Metabolism 22: 703, 1973.
Yalow R.S., Wu N. Additional studies on the nature of big gastrin. Gastroenterology 65: 19, 1973.
Sizemore G.W.. Heath H. III. Immunochemical heterogeneity of calcitonin in plasma of patients with medullary thyroid carcinoma. J.Clin. Invest. 55: 1111, 1975.
Taylor S.G., Schwartz T.B., Zannini J., Ryan W.G. Streptozotocin therapy for metastatic insulinoma. Arch. Intern. Med. 126: 654, 1970.
Schreibmann P.H., Goranski Dekoliren L., Arky R.A. Metastatic insulinoma treated with streptozotocin. Ann. Intern. Med. 74: 399, 1971.
Stauffacher W., Burr I., Gutzeit A., Beaven J., Veleminsky J., Renold A.E. Streptozotocin diabetes: time course of irreversible B-cell damage; further observation on prevention by nicotinamide (34439). Proc. Soc. Exp. Biol. Med. 133: 194, 1970.
Holst J.J., Helland S., Sngemannson S., Bang Pedersen N., von Shenk H. Functional studies in patients with the glucagonoma syndrome. Diabetologia 17: 151, 1979.
Boden G., Owen O., Rezvani I., Elfenbein B.I., Quickel K.E. An islet cell carcinoma containing glucagon and insulin Diabetes 26: 128, 1977.
De Wys W.D., Stoll R., Au W.Y., Salisnjak M. Effects of streptozotocin on an islet cell carcinoma with hypercalcemia. Am. J. Med. 55: 671, 1973.
Stewart A.F., Horst R., Defots L.J., Cadman E.C., Lang R., Broadus A.E. Biochemical evaluation of patients with cancer-associated hypercalcemia. Evidence for humoral and non-humoral groups. N. Engl. J. Med. 303: 1377, 1980.
Author information
Authors and Affiliations
Additional information
CNR Grant. N. 83.02857.56115.08250.
Rights and permissions
About this article
Cite this article
Del Prato, S., Rovira, A., Tessari, P. et al. Effect of streptozotocin in a case of glucagon-secreting malignant islets-cell tumor. J Endocrinol Invest 7, 111–116 (1984). https://doi.org/10.1007/BF03348399
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348399